This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Feuerstein's Biotech-Stock Mailbag

I hope everyone printed this week's column on FDA approval decision dates for 2008. You've told me this is the kind of information that biotech investors crave, so I hope the list helps in planning for next year.

I'm working on another calendar detailing upcoming phase III trial results, so look for that in the next week.

Another note about the FDA calendar: Several people wondered why I left off companies like Genitope (GTOP), Dendreon (DNDN) or Pain Therapeutics (PTIE).

As I said, I omitted companies that either 1) didn't have phase III data reported yet, or 2) hadn't yet filed for FDA approval.

Once a company files with the FDA and the application is accepted, they'll be put on the list. I'll update the calendar as we move through next year.

Speaking of Pain Therapeutics, the company is the subject of my first email, from Robin K:

"Adam, you correctly called out Remi Barbier a while ago on his 'fuzzy math.' What are your thoughts on [Thursday's] Remoxy results?"

A blast from the past. Robin is referring to a column from June 2004 about a study run by Pain Therapeutics' demonstrating the superior abuse-resistant qualities of its painkiller Remoxy over Oxycontin.

As I pointed out back then, the claims of superiority made by Pain Therapeutics and its CEO Remi Barbier were overstated because someone at the company didn't know how to use a calculator. In other words, the math in the press release was wrong.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GTOP $0.00 20.00%
DNDN $0.06 -6.02%
PTIE $2.32 -6.45%
AAPL $94.19 -1.04%
FB $118.06 0.54%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs